schliessen

Filtern

 

Bibliotheken

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess wh... Full description

Journal Title: The lancet oncology 2019-07, Vol.20 (7), p.984-997
Main Author: Cortes, Jorge E
Other Authors: Khaled, Samer , Martinelli, Giovanni , Perl, Alexander E , Ganguly, Siddhartha , Russell, Nigel , Krämer, Alwin , Dombret, Hervé , Hogge, Donna , Jonas, Brian A , Leung, Anskar Yu-Hung , Mehta, Priyanka , Montesinos, Pau , Radsak, Markus , Sica, Simona , Arunachalam, Meena , Holmes, Melissa , Kobayashi, Ken , Namuyinga, Ruth , Ge, Nanxiang , Yver, Antoine , Zhang, Yufen , Levis, Mark J
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 1470-2045
Link: https://www.ncbi.nlm.nih.gov/pubmed/31175001
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_2251697598
title: Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
format: Article
creator:
  • Cortes, Jorge E
  • Khaled, Samer
  • Martinelli, Giovanni
  • Perl, Alexander E
  • Ganguly, Siddhartha
  • Russell, Nigel
  • Krämer, Alwin
  • Dombret, Hervé
  • Hogge, Donna
  • Jonas, Brian A
  • Leung, Anskar Yu-Hung
  • Mehta, Priyanka
  • Montesinos, Pau
  • Radsak, Markus
  • Sica, Simona
  • Arunachalam, Meena
  • Holmes, Melissa
  • Kobayashi, Ken
  • Namuyinga, Ruth
  • Ge, Nanxiang
  • Yver, Antoine
  • Zhang, Yufen
  • Levis, Mark J
subjects:
  • Blood
  • Bone marrow
  • Cancer
  • Cell survival
  • Chemotherapy
  • Clinical trials
  • Colony-stimulating factor
  • Cytarabine
  • Etoposide
  • Fever
  • Fludarabine
  • Granulocyte colony-stimulating factor
  • Infections
  • Intravenous administration
  • Leukemia
  • Leukocytes (granulocytic)
  • Medical prognosis
  • Mitoxantrone
  • Mutation
  • Nausea
  • Neutropenia
  • Oncology
  • Patients
  • Pneumonia
  • Prognosis
  • Remission
  • Sepsis
  • Septic shock
  • Stem cell transplantation
  • Studies
  • Transplants & implants
ispartof: The lancet oncology, 2019-07, Vol.20 (7), p.984-997
description: Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy. QuANTUM-R is a randomised, controlled, phase 3 trial done at 152 hospitals and cancer centres in 19 countries. Eligible patients aged 18 years or older with ECOG performance status 0–2 with relapsed or refractory (duration of first composite complete remission ≤6 months) FLT3-ITD acute myeloid leukaemia after standard therapy with or without allogeneic haemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: subcutaneous low-dose cytarabine (subcutaneous injection of cytarabine 20 mg twice daily on days 1–10 of 28-day cycles); intravenous infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1–5 of up to two 28-day cycles); or intravenous granulocyte colony-stimulating factor (300 μg/m2 per day or 5 μg/kg per day subcutaneously on days 1–5), fludarabine (intravenous infusion 30 mg/m2 per day on days 2–6), cytarabine (intravenous infusion 2000 mg/m2 per day on days 2–6), and idarubicin (intravenous infusion 10 mg/m2 per day on days 2–4 in up to two 28-day cycles). Patients proceeding to haemopoietic stem-cell transplantation after quizartinib could resume quizartinib after haemopoietic stem-cell transplantation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02039726, and follow-up is ongoing. Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy. Four patients in the quizartinib group and 28 in the chemotherapy group were not treated. Median follow-up was 23·5 months (IQR 15·4–32·3). Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0·76 [95% CI 0·58–0·98; p=0·02]). Media
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1470-2045
fulltext: fulltext
issn:
  • 1470-2045
  • 1474-5488
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.8435209
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_2251697598
sourceformatXML
sourcesystemPC
galeidA591843964
sourcerecordidA591843964
originalsourceidFETCH-LOGICAL-c452t-242a2ea3d97494d08ce031fa9c3b706ca55ab8812497681d0b02c980a9ae9e383
addsrcrecordideNqFktFu0zAUhiMEYmPwCCBL3HRSM-wkbuJxgarBYFIBDbpr68Q5XT2cONhOpfJUPCJOO0BMSFMucnz0_b-OzvmT5DmjJ4yy2auvrChpmtGCT5g4zinjNKUPksPYLlJeVNXDXb1HDpIn3t9QykpG-ePkIGes5PF5mPy8HPQPcEF3uiYbdH7wxIPZwDUStcbWhjU66LdEd8Shgd5jQ6yL9cqBCtZtyflimacXy7cE1BCQtFs0VjfE4PANsNVAJpfD_NPy6mP65fiUAGkHE7TCLjicEgddY1sdXadE2dizxoy17bFLDdRopqRfg0eSk-A0mKfJoxUYj89u_0fJ1fm75dmHdPH5_cXZfJGqgmchzYoMMoS8EWUhioZWCmnOViBUXpd0poBzqKuKZYUoZxVraE0zJSoKAlBgXuVHyWTv2zv7fUAfZJxSoTHQoR28zDLOZqLkYkRf3kFv7OC6ON1IUT4rqpz9pa7BoNTdyoa4wdFUzrlgVZGLWRGpk_9Q8WviKuOCcKVj_x8B3wuUs97Hs8je6RbcVjIqx6TIXVLkGAPJhNwlRdKoe3E79FC32PxR_Y5GBF7fMVY6QNDjkUCbe-3f7NUYb7TR6KRXGjuFjXaogmysvsfhFyiZ3n8
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid2250564831
display
typearticle
titleQuizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
sourceAlma/SFX Local Collection
creatorCortes, Jorge E ; Khaled, Samer ; Martinelli, Giovanni ; Perl, Alexander E ; Ganguly, Siddhartha ; Russell, Nigel ; Krämer, Alwin ; Dombret, Hervé ; Hogge, Donna ; Jonas, Brian A ; Leung, Anskar Yu-Hung ; Mehta, Priyanka ; Montesinos, Pau ; Radsak, Markus ; Sica, Simona ; Arunachalam, Meena ; Holmes, Melissa ; Kobayashi, Ken ; Namuyinga, Ruth ; Ge, Nanxiang ; Yver, Antoine ; Zhang, Yufen ; Levis, Mark J
creatorcontribCortes, Jorge E ; Khaled, Samer ; Martinelli, Giovanni ; Perl, Alexander E ; Ganguly, Siddhartha ; Russell, Nigel ; Krämer, Alwin ; Dombret, Hervé ; Hogge, Donna ; Jonas, Brian A ; Leung, Anskar Yu-Hung ; Mehta, Priyanka ; Montesinos, Pau ; Radsak, Markus ; Sica, Simona ; Arunachalam, Meena ; Holmes, Melissa ; Kobayashi, Ken ; Namuyinga, Ruth ; Ge, Nanxiang ; Yver, Antoine ; Zhang, Yufen ; Levis, Mark J
descriptionPatients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy. QuANTUM-R is a randomised, controlled, phase 3 trial done at 152 hospitals and cancer centres in 19 countries. Eligible patients aged 18 years or older with ECOG performance status 0–2 with relapsed or refractory (duration of first composite complete remission ≤6 months) FLT3-ITD acute myeloid leukaemia after standard therapy with or without allogeneic haemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: subcutaneous low-dose cytarabine (subcutaneous injection of cytarabine 20 mg twice daily on days 1–10 of 28-day cycles); intravenous infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1–5 of up to two 28-day cycles); or intravenous granulocyte colony-stimulating factor (300 μg/m2 per day or 5 μg/kg per day subcutaneously on days 1–5), fludarabine (intravenous infusion 30 mg/m2 per day on days 2–6), cytarabine (intravenous infusion 2000 mg/m2 per day on days 2–6), and idarubicin (intravenous infusion 10 mg/m2 per day on days 2–4 in up to two 28-day cycles). Patients proceeding to haemopoietic stem-cell transplantation after quizartinib could resume quizartinib after haemopoietic stem-cell transplantation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02039726, and follow-up is ongoing. Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy. Four patients in the quizartinib group and 28 in the chemotherapy group were not treated. Median follow-up was 23·5 months (IQR 15·4–32·3). Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0·76 [95% CI 0·58–0·98; p=0·02]). Median overall survival was 6·2 months (5·3–7·2) in the quizartinib group and 4·7 months (4·0–5·5) in the chemotherapy group. The most common non-haematological grade 3–5 treatment-emergent adverse events (within ≤30 days of last dose or >30 days if suspected to be a treatment-related event) for quizartinib (241 patients) and chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy), pneumonia (29 [12%] vs eight [9%]), and hypokalaemia (28 [12%] vs eight [9%]). The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and nausea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group. Grade 3 QT prolongation in the quizartinib group was uncommon (eight [3%] by central reading, ten [4%] by investigator report); no grade 4 events occurred. There were 80 (33%) treatment-emergent deaths in the quizartinib group (31 [13%] of which were due to adverse events) and 16 (17%) in the chemotherapy group (nine [10%] of which were due to adverse events). Treatment with quizartinib had a survival benefit versus salvage chemotherapy and had a manageable safety profile in patients with rapidly proliferative disease and very poor prognosis. Quizartinib could be considered a new standard of care. Given that there are only a few available treatment options, this study highlights the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor. Daiichi Sankyo.
identifier
0ISSN: 1470-2045
1EISSN: 1474-5488
2DOI: 10.1016/S1470-2045(19)30150-0
3PMID: 31175001
languageeng
publisherEngland: Elsevier Ltd
subjectBlood ; Bone marrow ; Cancer ; Cell survival ; Chemotherapy ; Clinical trials ; Colony-stimulating factor ; Cytarabine ; Etoposide ; Fever ; Fludarabine ; Granulocyte colony-stimulating factor ; Infections ; Intravenous administration ; Leukemia ; Leukocytes (granulocytic) ; Medical prognosis ; Mitoxantrone ; Mutation ; Nausea ; Neutropenia ; Oncology ; Patients ; Pneumonia ; Prognosis ; Remission ; Sepsis ; Septic shock ; Stem cell transplantation ; Studies ; Transplants & implants
ispartofThe lancet oncology, 2019-07, Vol.20 (7), p.984-997
rights
02019 Elsevier Ltd
1Copyright © 2019 Elsevier Ltd. All rights reserved.
2COPYRIGHT 2019 Elsevier B.V.
32019. Elsevier Ltd
lds50peer_reviewed
citedbyFETCH-LOGICAL-c452t-242a2ea3d97494d08ce031fa9c3b706ca55ab8812497681d0b02c980a9ae9e383
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31175001$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Cortes, Jorge E
1Khaled, Samer
2Martinelli, Giovanni
3Perl, Alexander E
4Ganguly, Siddhartha
5Russell, Nigel
6Krämer, Alwin
7Dombret, Hervé
8Hogge, Donna
9Jonas, Brian A
10Leung, Anskar Yu-Hung
11Mehta, Priyanka
12Montesinos, Pau
13Radsak, Markus
14Sica, Simona
15Arunachalam, Meena
16Holmes, Melissa
17Kobayashi, Ken
18Namuyinga, Ruth
19Ge, Nanxiang
20Yver, Antoine
21Zhang, Yufen
22Levis, Mark J
title
0Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
1The lancet oncology
addtitleLancet Oncol
descriptionPatients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy. QuANTUM-R is a randomised, controlled, phase 3 trial done at 152 hospitals and cancer centres in 19 countries. Eligible patients aged 18 years or older with ECOG performance status 0–2 with relapsed or refractory (duration of first composite complete remission ≤6 months) FLT3-ITD acute myeloid leukaemia after standard therapy with or without allogeneic haemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: subcutaneous low-dose cytarabine (subcutaneous injection of cytarabine 20 mg twice daily on days 1–10 of 28-day cycles); intravenous infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1–5 of up to two 28-day cycles); or intravenous granulocyte colony-stimulating factor (300 μg/m2 per day or 5 μg/kg per day subcutaneously on days 1–5), fludarabine (intravenous infusion 30 mg/m2 per day on days 2–6), cytarabine (intravenous infusion 2000 mg/m2 per day on days 2–6), and idarubicin (intravenous infusion 10 mg/m2 per day on days 2–4 in up to two 28-day cycles). Patients proceeding to haemopoietic stem-cell transplantation after quizartinib could resume quizartinib after haemopoietic stem-cell transplantation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02039726, and follow-up is ongoing. Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy. Four patients in the quizartinib group and 28 in the chemotherapy group were not treated. Median follow-up was 23·5 months (IQR 15·4–32·3). Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0·76 [95% CI 0·58–0·98; p=0·02]). Median overall survival was 6·2 months (5·3–7·2) in the quizartinib group and 4·7 months (4·0–5·5) in the chemotherapy group. The most common non-haematological grade 3–5 treatment-emergent adverse events (within ≤30 days of last dose or >30 days if suspected to be a treatment-related event) for quizartinib (241 patients) and chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy), pneumonia (29 [12%] vs eight [9%]), and hypokalaemia (28 [12%] vs eight [9%]). The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and nausea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group. Grade 3 QT prolongation in the quizartinib group was uncommon (eight [3%] by central reading, ten [4%] by investigator report); no grade 4 events occurred. There were 80 (33%) treatment-emergent deaths in the quizartinib group (31 [13%] of which were due to adverse events) and 16 (17%) in the chemotherapy group (nine [10%] of which were due to adverse events). Treatment with quizartinib had a survival benefit versus salvage chemotherapy and had a manageable safety profile in patients with rapidly proliferative disease and very poor prognosis. Quizartinib could be considered a new standard of care. Given that there are only a few available treatment options, this study highlights the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor. Daiichi Sankyo.
subject
0Blood
1Bone marrow
2Cancer
3Cell survival
4Chemotherapy
5Clinical trials
6Colony-stimulating factor
7Cytarabine
8Etoposide
9Fever
10Fludarabine
11Granulocyte colony-stimulating factor
12Infections
13Intravenous administration
14Leukemia
15Leukocytes (granulocytic)
16Medical prognosis
17Mitoxantrone
18Mutation
19Nausea
20Neutropenia
21Oncology
22Patients
23Pneumonia
24Prognosis
25Remission
26Sepsis
27Septic shock
28Stem cell transplantation
29Studies
30Transplants & implants
issn
01470-2045
11474-5488
fulltexttrue
rsrctypearticle
creationdate2019
recordtypearticle
recordideNqFktFu0zAUhiMEYmPwCCBL3HRSM-wkbuJxgarBYFIBDbpr68Q5XT2cONhOpfJUPCJOO0BMSFMucnz0_b-OzvmT5DmjJ4yy2auvrChpmtGCT5g4zinjNKUPksPYLlJeVNXDXb1HDpIn3t9QykpG-ePkIGes5PF5mPy8HPQPcEF3uiYbdH7wxIPZwDUStcbWhjU66LdEd8Shgd5jQ6yL9cqBCtZtyflimacXy7cE1BCQtFs0VjfE4PANsNVAJpfD_NPy6mP65fiUAGkHE7TCLjicEgddY1sdXadE2dizxoy17bFLDdRopqRfg0eSk-A0mKfJoxUYj89u_0fJ1fm75dmHdPH5_cXZfJGqgmchzYoMMoS8EWUhioZWCmnOViBUXpd0poBzqKuKZYUoZxVraE0zJSoKAlBgXuVHyWTv2zv7fUAfZJxSoTHQoR28zDLOZqLkYkRf3kFv7OC6ON1IUT4rqpz9pa7BoNTdyoa4wdFUzrlgVZGLWRGpk_9Q8WviKuOCcKVj_x8B3wuUs97Hs8je6RbcVjIqx6TIXVLkGAPJhNwlRdKoe3E79FC32PxR_Y5GBF7fMVY6QNDjkUCbe-3f7NUYb7TR6KRXGjuFjXaogmysvsfhFyiZ3n8
startdate201907
enddate201907
creator
0Cortes, Jorge E
1Khaled, Samer
2Martinelli, Giovanni
3Perl, Alexander E
4Ganguly, Siddhartha
5Russell, Nigel
6Krämer, Alwin
7Dombret, Hervé
8Hogge, Donna
9Jonas, Brian A
10Leung, Anskar Yu-Hung
11Mehta, Priyanka
12Montesinos, Pau
13Radsak, Markus
14Sica, Simona
15Arunachalam, Meena
16Holmes, Melissa
17Kobayashi, Ken
18Namuyinga, Ruth
19Ge, Nanxiang
20Yver, Antoine
21Zhang, Yufen
22Levis, Mark J
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
0NPM
1AAYXX
2CITATION
3BSHEE
40TZ
53V.
67RV
77TO
87X7
97XB
1088E
118AO
128C1
138C2
148FI
158FJ
168FK
17ABUWG
18BENPR
19FYUFA
20GHDGH
21H94
22K9.
23KB0
24M0S
25M1P
26NAPCQ
27PQEST
28PQQKQ
29PQUKI
30PRINS
317X8
sort
creationdate201907
titleQuizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
authorCortes, Jorge E ; Khaled, Samer ; Martinelli, Giovanni ; Perl, Alexander E ; Ganguly, Siddhartha ; Russell, Nigel ; Krämer, Alwin ; Dombret, Hervé ; Hogge, Donna ; Jonas, Brian A ; Leung, Anskar Yu-Hung ; Mehta, Priyanka ; Montesinos, Pau ; Radsak, Markus ; Sica, Simona ; Arunachalam, Meena ; Holmes, Melissa ; Kobayashi, Ken ; Namuyinga, Ruth ; Ge, Nanxiang ; Yver, Antoine ; Zhang, Yufen ; Levis, Mark J
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c452t-242a2ea3d97494d08ce031fa9c3b706ca55ab8812497681d0b02c980a9ae9e383
rsrctypearticles
prefilterarticles
languageeng
creationdate2019
topic
0Blood
1Bone marrow
2Cancer
3Cell survival
4Chemotherapy
5Clinical trials
6Colony-stimulating factor
7Cytarabine
8Etoposide
9Fever
10Fludarabine
11Granulocyte colony-stimulating factor
12Infections
13Intravenous administration
14Leukemia
15Leukocytes (granulocytic)
16Medical prognosis
17Mitoxantrone
18Mutation
19Nausea
20Neutropenia
21Oncology
22Patients
23Pneumonia
24Prognosis
25Remission
26Sepsis
27Septic shock
28Stem cell transplantation
29Studies
30Transplants & implants
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Cortes, Jorge E
1Khaled, Samer
2Martinelli, Giovanni
3Perl, Alexander E
4Ganguly, Siddhartha
5Russell, Nigel
6Krämer, Alwin
7Dombret, Hervé
8Hogge, Donna
9Jonas, Brian A
10Leung, Anskar Yu-Hung
11Mehta, Priyanka
12Montesinos, Pau
13Radsak, Markus
14Sica, Simona
15Arunachalam, Meena
16Holmes, Melissa
17Kobayashi, Ken
18Namuyinga, Ruth
19Ge, Nanxiang
20Yver, Antoine
21Zhang, Yufen
22Levis, Mark J
collection
0PubMed
1CrossRef
2Academic OneFile (A&I only)
3Pharma and Biotech Premium PRO
4ProQuest Central (Corporate)
5Nursing & Allied Health Database
6Oncogenes and Growth Factors Abstracts
7Health & Medical Collection
8ProQuest Central (purchase pre-March 2016)
9Medical Database (Alumni Edition)
10ProQuest Pharma Collection
11Public Health Database
12Lancet Titles
13Hospital Premium Collection
14Hospital Premium Collection (Alumni Edition)
15ProQuest Central (Alumni) (purchase pre-March 2016)
16ProQuest Central (Alumni Edition)
17ProQuest Central
18Health Research Premium Collection
19Health Research Premium Collection (Alumni)
20AIDS and Cancer Research Abstracts
21ProQuest Health & Medical Complete (Alumni)
22Nursing & Allied Health Database (Alumni Edition)
23Health & Medical Collection (Alumni Edition)
24Medical Database
25Nursing & Allied Health Premium
26ProQuest One Academic Eastern Edition
27ProQuest One Academic
28ProQuest One Academic UKI Edition
29ProQuest Central China
30MEDLINE - Academic
jtitleThe lancet oncology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Cortes, Jorge E
1Khaled, Samer
2Martinelli, Giovanni
3Perl, Alexander E
4Ganguly, Siddhartha
5Russell, Nigel
6Krämer, Alwin
7Dombret, Hervé
8Hogge, Donna
9Jonas, Brian A
10Leung, Anskar Yu-Hung
11Mehta, Priyanka
12Montesinos, Pau
13Radsak, Markus
14Sica, Simona
15Arunachalam, Meena
16Holmes, Melissa
17Kobayashi, Ken
18Namuyinga, Ruth
19Ge, Nanxiang
20Yver, Antoine
21Zhang, Yufen
22Levis, Mark J
formatjournal
genrearticle
ristypeJOUR
atitleQuizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
jtitleThe lancet oncology
addtitleLancet Oncol
date2019-07
risdate2019
volume20
issue7
spage984
epage997
pages984-997
issn1470-2045
eissn1474-5488
abstractPatients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy. QuANTUM-R is a randomised, controlled, phase 3 trial done at 152 hospitals and cancer centres in 19 countries. Eligible patients aged 18 years or older with ECOG performance status 0–2 with relapsed or refractory (duration of first composite complete remission ≤6 months) FLT3-ITD acute myeloid leukaemia after standard therapy with or without allogeneic haemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: subcutaneous low-dose cytarabine (subcutaneous injection of cytarabine 20 mg twice daily on days 1–10 of 28-day cycles); intravenous infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1–5 of up to two 28-day cycles); or intravenous granulocyte colony-stimulating factor (300 μg/m2 per day or 5 μg/kg per day subcutaneously on days 1–5), fludarabine (intravenous infusion 30 mg/m2 per day on days 2–6), cytarabine (intravenous infusion 2000 mg/m2 per day on days 2–6), and idarubicin (intravenous infusion 10 mg/m2 per day on days 2–4 in up to two 28-day cycles). Patients proceeding to haemopoietic stem-cell transplantation after quizartinib could resume quizartinib after haemopoietic stem-cell transplantation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02039726, and follow-up is ongoing. Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy. Four patients in the quizartinib group and 28 in the chemotherapy group were not treated. Median follow-up was 23·5 months (IQR 15·4–32·3). Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0·76 [95% CI 0·58–0·98; p=0·02]). Median overall survival was 6·2 months (5·3–7·2) in the quizartinib group and 4·7 months (4·0–5·5) in the chemotherapy group. The most common non-haematological grade 3–5 treatment-emergent adverse events (within ≤30 days of last dose or >30 days if suspected to be a treatment-related event) for quizartinib (241 patients) and chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy), pneumonia (29 [12%] vs eight [9%]), and hypokalaemia (28 [12%] vs eight [9%]). The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and nausea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group. Grade 3 QT prolongation in the quizartinib group was uncommon (eight [3%] by central reading, ten [4%] by investigator report); no grade 4 events occurred. There were 80 (33%) treatment-emergent deaths in the quizartinib group (31 [13%] of which were due to adverse events) and 16 (17%) in the chemotherapy group (nine [10%] of which were due to adverse events). Treatment with quizartinib had a survival benefit versus salvage chemotherapy and had a manageable safety profile in patients with rapidly proliferative disease and very poor prognosis. Quizartinib could be considered a new standard of care. Given that there are only a few available treatment options, this study highlights the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor. Daiichi Sankyo.
copEngland
pubElsevier Ltd
pmid31175001
doi10.1016/S1470-2045(19)30150-0